TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Music Therapy in Methodist Homes: a Cluster Randomised Controlled Trial Including Mixed Methods Analysis Investigating the Efficacy of the Impact of a Music Therapy Programme on Caring for People With Dementia Who Have Behavioural Symptoms.
Brief Summary: The study is a cluster randomised control trial, which aims to investigate the effectiveness of music therapy in minimising Behavioural and Psychological Symptoms of Dementia (BPSD) in older adults with dementia. In particular, the study aims to identify the main components of music therapy that are key in achieving this. The study will also explore carers' perceptions of music therapy, and investigate whether carers become more attentive to patients' needs and more able to manage patients' BPSD as a result of the music therapy programme.


Options:
A: Arm Label: All practices; Type: OTHER; Interventions: Behavioral: DQIP Intervention | Intervention Type: BEHAVIORAL; Name: DQIP Intervention; Assigned to Arm(s): All practices
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: TREA (Treatment Routes for Exploring Agitation) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Placebo Control Group | Intervention Type: BEHAVIORAL; Name: TREA (Treatment Routes for Exploring Agitation); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Placebo Control Group; Assigned to Arm(s): 2
C: Arm Label: Music Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Music Therapy | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Music Therapy; Assigned to Arm(s): Music Therapy
D: Arm Label: Montessori Method for Dementia; Type: EXPERIMENTAL; Interventions: Behavioral: Montessori Method for Dementia | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Montessori Method for Dementia; Assigned to Arm(s): Montessori Method for Dementia | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Music Therapy in Methodist Homes: a Cluster Randomised Controlled Trial Including Mixed Methods Analysis Investigating the Efficacy of the Impact of a Music Therapy Programme on Caring for People With Dementia Who Have Behavioural Symptoms.
Brief Summary: The study is a cluster randomised control trial, which aims to investigate the effectiveness of music therapy in minimising Behavioural and Psychological Symptoms of Dementia (BPSD) in older adults with dementia. In particular, the study aims to identify the main components of music therapy that are key in achieving this. The study will also explore carers' perceptions of music therapy, and investigate whether carers become more attentive to patients' needs and more able to manage patients' BPSD as a result of the music therapy programme.


Options:
A: Arm Label: All practices; Type: OTHER; Interventions: Behavioral: DQIP Intervention | Intervention Type: BEHAVIORAL; Name: DQIP Intervention; Assigned to Arm(s): All practices
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: TREA (Treatment Routes for Exploring Agitation) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Placebo Control Group | Intervention Type: BEHAVIORAL; Name: TREA (Treatment Routes for Exploring Agitation); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Placebo Control Group; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Activity matched to interest | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Activity matched to function | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Activity matched to both interest and function | Arm Label: 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Activity matched to interest; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Activity matched to function; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Activity matched to both interest and function; Assigned to Arm(s): 3
D: Arm Label: Music Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Music Therapy | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Music Therapy; Assigned to Arm(s): Music Therapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Single Arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With 17p Deletion (RESONATE™-17)
Brief Summary: An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with 17p Deletion


Options:
A: Arm Label: Idelalisib+bendamustine+rituximab; Type: EXPERIMENTAL; Interventions: Drug: Idelalisib, Drug: Rituximab, Drug: Bendamustine | Arm Label: Placebo to match idelalisib+bendamustine+rituximab; Type: PLACEBO_COMPARATOR; Interventions: Drug: Rituximab, Drug: Bendamustine, Drug: Placebo to match idelalisib | Intervention Type: DRUG; Name: Idelalisib; Assigned to Arm(s): Idelalisib+bendamustine+rituximab | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Idelalisib+bendamustine+rituximab, Placebo to match idelalisib+bendamustine+rituximab | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Idelalisib+bendamustine+rituximab, Placebo to match idelalisib+bendamustine+rituximab | Intervention Type: DRUG; Name: Placebo to match idelalisib; Assigned to Arm(s): Placebo to match idelalisib+bendamustine+rituximab
B: Arm Label: Ofatumumab; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab | Arm Label: Physicians' Choice; Type: ACTIVE_COMPARATOR; Interventions: Drug: Physicians' Choice | Intervention Type: DRUG; Name: Ofatumumab; Assigned to Arm(s): Ofatumumab | Intervention Type: DRUG; Name: Physicians' Choice; Assigned to Arm(s): Physicians' Choice
C: Arm Label: ibrutinib; Type: EXPERIMENTAL; Interventions: Drug: Ibrutinib | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): ibrutinib
D: Arm Label: Bendamustine, rituximab, lenalidomide; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: Rituximab, Drug: Lenalidomide | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Bendamustine, rituximab, lenalidomide | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Bendamustine, rituximab, lenalidomide | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): Bendamustine, rituximab, lenalidomide

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pediatrician Advice, Family Counseling & SHS Reduction for Underserved Children
Brief Summary: The study's primary aim is to test the hypothesis that an intervention integrating pediatric clinic-level quality improvement with home-level behavioral counseling (CQI+BC) will result in greater reductions in child cotinine (a biomarker of secondhand smoke exposure) and reported cigarettes exposed/day than a clinic-level quality improvement plus attention control intervention (CQI+A). A secondary aim is to test the hypothesis that relative to CQI+A, CQI+BC will result in higher cotinine-verified, 7-day point prevalence quit rate among parents.


Options:
A: Arm Label: Clinic Quality Improvement + Behavioral Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Clinic Quality Improvement + Behavioral Counseling | Arm Label: Clinic Quality Improvement + Attention Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Clinic Quality Improvement + Attention Control | Intervention Type: BEHAVIORAL; Name: Clinic Quality Improvement + Behavioral Counseling; Assigned to Arm(s): Clinic Quality Improvement + Behavioral Counseling | Intervention Type: BEHAVIORAL; Name: Clinic Quality Improvement + Attention Control; Assigned to Arm(s): Clinic Quality Improvement + Attention Control
B: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A
C: Arm Label: Longitudinal Care; Type: EXPERIMENTAL; Interventions: Behavioral: smoking cessation | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: smoking cessation | Intervention Type: BEHAVIORAL; Name: smoking cessation; Assigned to Arm(s): Longitudinal Care, Usual Care
D: Arm Label: Enhanced PTSD Health Buddy and Motivational Interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Motivation Interviewing Counseling | Arm Label: Usual PTSD Health Buddy Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Motivation Interviewing Counseling; Assigned to Arm(s): Enhanced PTSD Health Buddy and Motivational Interviewing

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pediatrician Advice, Family Counseling & SHS Reduction for Underserved Children
Brief Summary: The study's primary aim is to test the hypothesis that an intervention integrating pediatric clinic-level quality improvement with home-level behavioral counseling (CQI+BC) will result in greater reductions in child cotinine (a biomarker of secondhand smoke exposure) and reported cigarettes exposed/day than a clinic-level quality improvement plus attention control intervention (CQI+A). A secondary aim is to test the hypothesis that relative to CQI+A, CQI+BC will result in higher cotinine-verified, 7-day point prevalence quit rate among parents.


Options:
A: Arm Label: Clinic Quality Improvement + Behavioral Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Clinic Quality Improvement + Behavioral Counseling | Arm Label: Clinic Quality Improvement + Attention Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Clinic Quality Improvement + Attention Control | Intervention Type: BEHAVIORAL; Name: Clinic Quality Improvement + Behavioral Counseling; Assigned to Arm(s): Clinic Quality Improvement + Behavioral Counseling | Intervention Type: BEHAVIORAL; Name: Clinic Quality Improvement + Attention Control; Assigned to Arm(s): Clinic Quality Improvement + Attention Control
B: Arm Label: Behavioral; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing Intervention for ETS Reduction | Arm Label: Education Only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational Program for ETS Reduction | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing Intervention for ETS Reduction; Assigned to Arm(s): Behavioral | Intervention Type: BEHAVIORAL; Name: Educational Program for ETS Reduction; Assigned to Arm(s): Education Only
C: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Brief intervention based in clinical practice guide | Intervention Type: BEHAVIORAL; Name: Brief intervention based in clinical practice guide; Assigned to Arm(s): Lifestyle counseling
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Health Coach and HEPA Air cleaners | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Coach and HEPA air cleaners | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Coach and HEPA air cleaners | Intervention Type: BEHAVIORAL; Name: Health Coach and HEPA Air cleaners; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Health Coach and HEPA air cleaners; Assigned to Arm(s): 1, 2, 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Treatment-Naive Proliferative Diabetic Retinopathy
Brief Summary: To evaluate the efficacy of combination therapy with ranibizumab (RBZ) and panretinal photocoagulation (PRP) versus PRP alone in patients with treatment-naive bilateral proliferative diabetic retinopathy (PDR) as measured by mean change in visual acuity (VA), mean change in central retinal thickness (CRT) as measured by time-domain optic coherence tomography (TD-OCT) and incidence of vitreous hemorrhage (VH).


Options:
A: Arm Label: Placebo first (scheme 2); Type: OTHER; Interventions: Drug: potassium diclofenac | Arm Label: Diclofenac first (scheme 1); Type: OTHER; Interventions: Drug: potassium diclofenac | Intervention Type: DRUG; Name: potassium diclofenac; Assigned to Arm(s): Diclofenac first (scheme 1), Placebo first (scheme 2)
B: Arm Label: Ranibizumab; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser therapy | Arm Label: Laser Therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laser therapy | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab | Intervention Type: PROCEDURE; Name: Laser therapy; Assigned to Arm(s): Laser Therapy, Ranibizumab
C: Arm Label: Anti-VEGF+Deferred PRP; Type: EXPERIMENTAL; Interventions: Drug: 0.5-mg Ranibizumab, Other: Deferred panretinal photocoagulation | Arm Label: Prompt PRP; Type: ACTIVE_COMPARATOR; Interventions: Other: Prompt Panretinal Photocoagulation | Intervention Type: OTHER; Name: Prompt Panretinal Photocoagulation; Assigned to Arm(s): Prompt PRP | Intervention Type: DRUG; Name: 0.5-mg Ranibizumab; Assigned to Arm(s): Anti-VEGF+Deferred PRP | Intervention Type: OTHER; Name: Deferred panretinal photocoagulation; Assigned to Arm(s): Anti-VEGF+Deferred PRP
D: Arm Label: A: Faricimab 6 mg Q8W; Type: EXPERIMENTAL; Interventions: Drug: Faricimab, Procedure: Sham Procedure | Arm Label: B: Faricimab 6 mg PTI; Type: EXPERIMENTAL; Interventions: Drug: Faricimab, Procedure: Sham Procedure | Arm Label: C: Aflibercept 2 mg Q8W; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aflibercept, Procedure: Sham Procedure | Intervention Type: DRUG; Name: Aflibercept; Assigned to Arm(s): C: Aflibercept 2 mg Q8W | Intervention Type: DRUG; Name: Faricimab; Assigned to Arm(s): A: Faricimab 6 mg Q8W, B: Faricimab 6 mg PTI | Intervention Type: PROCEDURE; Name: Sham Procedure; Assigned to Arm(s): A: Faricimab 6 mg Q8W, B: Faricimab 6 mg PTI, C: Aflibercept 2 mg Q8W

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of N6022 to Evaluate Safety and Pharmacokinetics in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation (SNO1)
Brief Summary: The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of N6022, and to obtain descriptive information on the effect of N6022 on biomarkers of CFTR function and inflammation in adult cystic fibrosis subjects who are homozygous for the F508del-CFTR mutation.


Options:
A: Arm Label: Treatment Period 1: LUM/IVA to LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: LUM/IVA | Arm Label: Treatment Period 1: Placebo (PBO) to LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: LUM/IVA | Arm Label: Treatment Period 1: Observational Cohort; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment Period 2: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: LUM/IVA | Intervention Type: DRUG; Name: LUM/IVA; Assigned to Arm(s): Treatment Period 1: LUM/IVA to LUM/IVA, Treatment Period 1: Placebo (PBO) to LUM/IVA | Intervention Type: DRUG; Name: LUM/IVA; Assigned to Arm(s): Treatment Period 2: LUM/IVA
B: Arm Label: TEZ/IVA; Type: ACTIVE_COMPARATOR; Interventions: Drug: TEZ/IVA, Drug: IVA, Drug: Placebo | Arm Label: VX-445/TEZ/IVA TC; Type: EXPERIMENTAL; Interventions: Drug: VX-445/TEZ/IVA, Drug: IVA, Drug: Placebo | Intervention Type: DRUG; Name: VX-445/TEZ/IVA; Assigned to Arm(s): VX-445/TEZ/IVA TC | Intervention Type: DRUG; Name: TEZ/IVA; Assigned to Arm(s): TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): TEZ/IVA, VX-445/TEZ/IVA TC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): TEZ/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): VX-445/TEZ/IVA TC
C: Arm Label: Triple Combination Arm; Type: EXPERIMENTAL; Interventions: Drug: ELX/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: ELX/TEZ/IVA; Assigned to Arm(s): Triple Combination Arm | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): Triple Combination Arm
D: Arm Label: N6022; Type: EXPERIMENTAL; Interventions: Drug: N6022 | Arm Label: Normal saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: N6022; Assigned to Arm(s): N6022 | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Normal saline

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multicenter, Randomized, Controlled, Parallel-group, Open Label Trial Evaluating Benefits of Nasal High Flow Therapy (HFT) in Preoxygenation Before Tracheal Intubation in Acute Hypoxemic Respiratory Failure
Brief Summary: Oro-tracheal intubation in intensive unit care(ICU) in acute hypoxemic respiratory failure after crash induction remains a critical event.

The aim of this study is to determine whether Nasal High Flow Therapy (HFT) Optiflow ® is more efficient than the face mask for preoxygenation before orotracheal intubation after crash induction in acute hypoxemic respiratory failure


Options:
A: Arm Label: Normoventilation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Hyperventilation; Type: EXPERIMENTAL; Interventions: Procedure: Hyperventilation | Intervention Type: PROCEDURE; Name: Hyperventilation; Assigned to Arm(s): Hyperventilation
B: Arm Label: THRIVE; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: THRIVE with nasopharyngeal airway; Type: ACTIVE_COMPARATOR; Interventions: Device: Nasopharyngeal airway | Intervention Type: DEVICE; Name: Nasopharyngeal airway; Assigned to Arm(s): THRIVE with nasopharyngeal airway
C: Arm Label: PREOXYFLOW; Type: EXPERIMENTAL; Interventions: Device: PREOXYFLOW | Arm Label: STANDARD FACE MASK; Type: ACTIVE_COMPARATOR; Interventions: Procedure: STANDARD FACE MASK | Intervention Type: DEVICE; Name: PREOXYFLOW; Assigned to Arm(s): PREOXYFLOW | Intervention Type: PROCEDURE; Name: STANDARD FACE MASK; Assigned to Arm(s): STANDARD FACE MASK
D: Arm Label: High Flow nasal cannula oxygen (HFNC); Type: EXPERIMENTAL; Interventions: Device: OPTIFLOW/ AIRVO | Arm Label: STANDARD high flow Face Mask (HFFM); Type: ACTIVE_COMPARATOR; Interventions: Procedure: STANDARD Face Mask | Intervention Type: DEVICE; Name: OPTIFLOW/ AIRVO; Assigned to Arm(s): High Flow nasal cannula oxygen (HFNC) | Intervention Type: PROCEDURE; Name: STANDARD Face Mask; Assigned to Arm(s): STANDARD high flow Face Mask (HFFM)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Active Video Games to Promote Physical Activity, Motor Performance and Quality of Life in Children With Cancer: an Intervention Study With 2-year Follow-up
Brief Summary: The aim of this study is to evaluate the efficacy and feasibility of active video gaming with regard to the promotion of physical activity and motor learning in children with cancer. Experienced fatigue, body mass index and the development of metabolic risk factors during treatment are also examined.


Options:
A: Arm Label: Active video games; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise based on active video gaming | Arm Label: Routine care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise based on active video gaming; Assigned to Arm(s): Active video games
B: Arm Label: Exercise (EX); Type: EXPERIMENTAL; Interventions: Other: EXERCISE (EX) | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Care | Intervention Type: OTHER; Name: EXERCISE (EX); Assigned to Arm(s): Exercise (EX) | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): Standard Care
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: exercise | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: exercise; Assigned to Arm(s): A
D: Arm Label: treatment (exercise); Type: EXPERIMENTAL; Interventions: Other: exercise training | Arm Label: control (usual care); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: exercise training; Assigned to Arm(s): treatment (exercise)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled Parallel Group Study in Subjects With Plaque Psoriasis
Brief Summary: This study is designed to evaluate the efficacy and safety of KHK4827 in subjects with moderate to severe plaque psoriasis in a randomized, double-blind, placebo-controlled, parallel group study. Pharmacokinetics of KHK4827 will also be assessed.


Options:
A: Arm Label: Secukinumab (AIN457) 75 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Secukinumab (AIN457) 150 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Secukinumab (AIN457) 300 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Placebo s.c.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Secukinumab (AIN457), Drug: Placebo | Intervention Type: DRUG; Name: Secukinumab (AIN457); Assigned to Arm(s): Placebo s.c., Secukinumab (AIN457) 150 mg s.c., Secukinumab (AIN457) 300 mg s.c., Secukinumab (AIN457) 75 mg s.c. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo s.c.
B: Arm Label: KHK4827 70mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: KHK4827 140mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: KHK4827 210mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: Placebo SC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: KHK4827; Assigned to Arm(s): KHK4827 140mg SC, KHK4827 210mg SC, KHK4827 70mg SC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo SC
C: Arm Label: Apremilast; Type: EXPERIMENTAL; Interventions: Drug: Apremilast, Drug: Placebo, Drug: Placebo-Apremilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Placebo-Apremilast | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Apremilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Apremilast, Placebo | Intervention Type: DRUG; Name: Placebo-Apremilast; Assigned to Arm(s): Apremilast, Placebo
D: Arm Label: Risankizumab; Type: EXPERIMENTAL; Interventions: Drug: Risankizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo solution for risankizumab | Intervention Type: DRUG; Name: Risankizumab; Assigned to Arm(s): Risankizumab | Intervention Type: DRUG; Name: Placebo solution for risankizumab; Assigned to Arm(s): Placebo

Answer: B